Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 20, 2020 01:32 ET | Source: Novartis International AG

Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial...
April 20, 2020 01:17 ET | Source: Novartis International AG

Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”

Technology has potential to reimagine treatment for amblyopia (“lazy eye”), a leading cause of vision loss in children and young adults1Acquisition expands the Novartis refractive disorder pipeline in...
April 16, 2020 01:15 ET | Source: Novartis International AG

Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine

Real-world evidence supports benefits seen in Aimovig clinical trials Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine Post-hoc and...
April 03, 2020 08:15 ET | Source: Novartis International AG

Novartis International AG: Schweiz erhält als erstes europäisches Land Hydroxychloroquin Spende von Novartis

Novartis hat zugesagt, weltweit bis zu 130 Millionen Dosen des Malariamittels Hydroxychloroquin zu spenden, um den Kampf gegen die COVID-19-Pandemie zu unterstützen.Sandoz, die Novartis Generika- und...
April 03, 2020 08:15 ET | Source: Novartis International AG

Novartis International AG : La Suisse est le premier pays européen à recevoir un don d’hydroxychloroquine de la part de Novartis

Novartis a promis un don mondial allant jusqu’à 130 millions de doses d’hydroxychloroquine, un antipaludique, afin d’apporter son soutien à la lutte contre la pandémie de COVID-19.Sandoz, la division...
April 02, 2020 17:05 ET | Source: Novartis International AG

Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program

New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm Cytokine storm is a type of severe immune overreaction that can result from coronavirus...
April 01, 2020 22:00 ET | Source: Novartis International AG

Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo

Basel, April 2, 2020 – Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement to sell the Sandoz US generic oral solids and dermatology businesses to...
March 28, 2020 11:00 ET | Source: Novartis International AG

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months1 Prespecified...
March 27, 2020 09:02 ET | Source: Novartis International AG

Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum

EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is based on Phase III PREVENT data1 If approved, Cosentyx would become...
March 27, 2020 08:59 ET | Source: Novartis International AG

AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)

Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, has been recommended for European Commission (EC) conditional approval for patients with spinal muscular atrophy (SMA) and...